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In patients with primary aldosteronism specific treatment provides prognostic benefit over optimal 27 
antihypertensive therapy and is therefore crucial to reduce mortality and morbidity in this subgroup 28 
of patients with hypertension. Prognostic relevance has been shown for adrenalectomy in unilateral 29 
disease, and for medical treatment with mineralocorticoid receptor antagonists in bilateral adrenal 30 
hyperplasia. Collectively, evidence points to the superiority of surgical treatment compared to 31 
medical treatment. The causal approach of removing the mineralocorticoid excess, as well as the 32 
often-accompanying glucocorticoid excess, might provide one biologically plausible explanation for 33 
the observation of slightly better outcomes with surgical therapy.  34 
However, in patients living with primary aldosteronism, medical treatment is often insufficient for 35 
three major reasons. First and foremost, no marker of sufficient aldosterone blockade has yet been 36 
established and therefore adequate treatment of the aldosterone excess is often dismissed as a 37 
treatment goal. Second, side effects often limit patient compliance. Third, as recommendations differ 38 
from other indications like heart failure, drug dosing is often inadequate.  39 
The aim of this review is first to provide an overview over medical treatment options, and second to 40 




Primary aldosteronism is the most common cause of surgically curable secondary hypertension. The 45 
estimated prevalence is 4-6% in patients living with hypertension in primary care, around 10% in 46 
specialized hypertensive clinics, and reaches 20% in patients with refractory hypertension (1). 47 
Primary aldosteronism is characterized by inappropriately high plasma aldosterone concentrations 48 
relative to suppressed plasma renin activity (2). A growing body of sound evidence suggests that the 49 
aldosterone excess poses a significantly increased risk of cardiometabolic disease via activation of the 50 
mineralocorticoid receptor (1, 3). This provides biologic plausibility for the observation that several 51 
studies have shown higher morbidity rates in patients with primary aldosteronism compared to 52 
matched patients with essential hypertension (4-8).  53 
Early specific medical or surgical treatment decreases the risk associated with primary aldosteronism 54 
and therefore has the potential to impact prognosis (9, 10).  55 
Of note, recent data suggests that in patients with resistant hypertension, despite the exclusion of 56 
primary aldosteronism, spironolactone and amiloride are superior to other antihypertensive 57 
medication in lowering blood pressure (11). This has been explained by their potential to counteract 58 
the increased salt retention in resistant hypertension, which is likely due to mild inappropriate 59 
aldosterone secretion. 60 
 61 
Types of primary aldosteronism and treatment options 62 
Primary aldosteronism is classified into unilateral and bilateral forms of the disease. These conditions 63 
must be distinguished because of different treatment approaches (1). While in unilateral disease, 64 
surgical treatment via adrenalectomy is considered the gold standard, in bilateral disease, medical 65 
treatment with mineralocorticoid receptor antagonists is the therapy of choice (1).  66 
Although there is controversy over whether adrenalectomy is superior to adequate medical 67 
treatment with regard to cardiovascular outcomes, lines of recent evidence from observational 68 
studies speak to the superiority of surgical treatment in unilateral disease (9, 12-16). For example, 69 
Rossi et al. showed a higher risk of atrial fibrillation in medically treated versus adrenalectomized PA 70 
patients (17) and in a study done by Strauch et al. arterial stiffness was reduced significantly by 71 
adrenalectomy but not after 1 year of spironolactone treatment (14). Moreover, a nationwide survey 72 
in Japan showed greater improvement of hypertension and hypokalemia in surgically treated PA 73 
patients compared to medical treatment with spironolactone (13). In the prospective SPARTACUS 74 
trial, which compared adrenal vein sampling with CT scan to determine treatment in primary 75 
aldosteronism, blood pressure was similar in surgically versus medically treated patients. However, 76 
patients who underwent adrenalectomy needed less (non-MRA) antihypertensive medication after 6 77 
and 12 months and showed higher quality of life compared to medically treated patients (18, 19). Of 78 
note, adrenalectomy results in clinical blood pressure remission in 17 to 62 % and in biochemical 79 
remission of aldosterone excess in 93 to 100 % (1, 15). Another layer of complexity is added by the 80 
emerging evidence that glucocorticoid co-secretion is very common in aldosterone producing 81 
adenomas as well as in bilateral hyperplasia (20, 21). This has been linked to the increased 82 
cardiovascular morbidity and mortality in primary aldosteronism, and could provide a biologically 83 
plausible explanation for the observation that adrenalectomy, which removes the glucocorticoid and 84 
aldosterone excess, has shown more favorable outcomes than medical treatment (9, 13, 14). 85 
Glucocorticoid co-secretion is associated with body mass index (BMI), insulin resistance (20), left 86 
ventricular hypertrophy  (21) and impaired glucose tolerance (22).  87 
Of note, surgical candidates with primary aldosteronism have a higher rate of persistent 88 
hypertension after adrenalectomy if preoperative plasma renin levels are not suppressed (23). This 89 
clinically unfavorable escape of renin from suppression by excess aldosterone has been explained by 90 
more severe renal damage and altered intra-glomerular hemodynamics leading to less favorable 91 
outcomes after treatment. Other factors that predict clinical success after adrenalectomy are known 92 
duration of hypertension, sex, antihypertensive medication dosage, body mass index, target organ 93 
damage, and size of the largest nodule as depicted by imaging (15). 94 
Noteworthy, a recently published study by Hundemer et. al. sheds new light on the treatment with 95 
mineralocorticoid receptor antagonists (3). In this retrospective analysis the authors compared data 96 
of 602 medically treated patients with primary aldosteronism with 41853 essential hypertension 97 
patients. Data were sourced from the Brigham and Women’s, the Massachusetts General and 98 
affiliate partner hospitals and included patients seen over a 25-year period (1991-2016). Patients 99 
whose baseline laboratory data were inconsistent with the diagnosis of primary aldosteronism 100 
(defined as aldosterone-to-renin-ratio <555 pmol/l per µg/l per h or plasma renin activity ≥1 µg/l per 101 
h or negative confirmatory testing) as well as patients with primary aldosteronism who underwent 102 
adrenalectomy, had a previous cardiovascular event or were not treated with MR antagonists were 103 
excluded from the analysis. The groups were matched by decade of age at study entry. Mean age (58 104 
years in the PA group, 57 years in the essential hypertension group) and BMI values (31.1 kg/m2 in 105 
the PA group, 29.8 kg/m2 in the essential hypertension) were quite high and the sex balance was 106 
fairly even (45% female in the PA group, 51% in the essential hypertension group). 107 
The results show an almost doubled incidence of cardiovascular events in patients with primary 108 
aldosteronism compared to the essential hypertension group during a follow-up of 7 years for 109 
patients with PA and 8.8 years for those with essential hypertension. Of note, in a subgroup analysis 110 
of 201 primary aldosteronism patients in whom plasma renin was measured at least 1 month after 111 
starting MR antagonists, there was a strong correlation between plasma renin activity and 112 
cardiovascular outcomes: those 67 patients with unsuppressed plasma renin activity (≥1 µg/l per h) 113 
showed an identical risk profile as the essential hypertension group, whereas those 134 patients with 114 
suppressed plasma renin activity had a risk profile almost three times higher, despite the fact that 115 
mean blood pressure did not differ between the groups (3, 24). The authors thus concluded that 116 
plasma renin activity might be a predictor of cardiovascular outcomes and may serve as a potential 117 
marker for treatment response. 118 
However, as John W. Funder pointed out in an accompanying editorial, there are several limitations 119 
that should provide caution against oversimplified inference (24). First, sodium plays a major role in 120 
renin regulation. With dietary sodium restriction, renin tends to rise whereas with sodium excess, 121 
renin is suppressed. This may be a confounder, because dietary sodium restriction has been linked to 122 
more favorable cardiovascular outcomes in PA (25), a parameter which was not available in the 123 
aforementioned study. Second, non-compliance, which leads to suppressed renin activity, is very 124 
common, particularly in men treated with spironolactone. Therefore, it may be hypothesized that 125 
non-compliance was overrepresented in the suppressed renin activity group (24). Another reason for 126 
non-suppressed renin levels could be simply a sloppy diagnosis of primary aldosteronism. It is worth 127 
mentioning that the aldosterone to renin ratio as a screening test is notoriously imprecise (26). The 128 
diagnostic criteria for primary aldosteronism used in this study were rather loose (3, 24), since 129 
confirmatory testing was only performed in 72%, and adrenal vein sampling in only 55%. In such a 130 
scenario, non-suppressed renin levels could also indicate presence of essential hypertension, which 131 
would explain the better cardiovascular long-term outcome. 132 
 133 
Advantages and disadvantages of different drugs 134 
Medical treatment options for PA are very limited. Treatment of choice are mineralocorticoid 135 
receptor antagonists, the most commonly used agents being spironolactone and eplerenone. In case 136 
of contraindications against MRA-therapy, potassium sparing diuretics like amiloride or triamteren 137 
are recommended, which are less effective (1, 27). 138 
In many countries including Germany, only spironolactone, a non-selective MR-antagonist which has 139 
been clinically applied since the early 1960s, has been approved for the therapy of primary 140 
aldosteronism (28). Upon administration spironolactone is rapidly dethioacetylated to its principal 141 
pharmacologically active metabolite canrenone. Recent data suggests that spironolactone as well as 142 
canrenone undergo further metabolization by adrenal enzymes (CYP11B1 and CYP11B2) into 143 
hydroxylation products with different pharmacological properties (28). Due to the extended 144 
metabolization the half-life of spironolactone is quite long (24-58 hours). Therefore, a one-time per 145 
day or even every other day administration has proven to be efficacious. An important downside to 146 
be considered with spironolactone is its anti-androgenic action due to its affinity to the androgen 147 
receptor. This causes a variety of dose-dependent adverse effects, especially in men which include 148 
painful gynecomastia and erectile dysfunction.  This might be one of the explanations for the 149 
commonly observed non-compliance (29). In the SPARTACUS trial the authors observed a high rate of 150 
antiandrogenic adverse events in both sexes: Gynecomastia, mastopathy, menstrual disturbances, 151 
erectile dysfunction, and decreased libido were present in 1% in the adrenalectomy group, but in 152 
57% of the spironolactone group. In consequence, 34% of patients were switched to eplerenone. 153 
The more selective MR-antagonist eplerenone, which at the right dose, has been proven to be 154 
equally efficacious as spironolactone, is not yet approved for the treatment of PA in many countries 155 
including Germany. However, its common use in heart failure makes it easily available and off-label-156 
use is common. The advantage of eplerenone over spironolactone is its relative selectiveness on the 157 
mineralocorticoid receptor, with no adverse anti-androgenic effects (29). In this context, eplerenone 158 
is a viable option to consider in patients with anti-androgenic complications under spironolactone 159 
treatment. In contrast to spironolactone, eplerenone is not converted into active metabolites (28). 160 
Therefore, eplerenone has a significantly shorter half-life of only 3-4 hours. This requires a twice daily 161 
administration (29). Moreover, this pharmacological agent is hepatically eliminated by CYP3A4, and 162 
therefore prone to interact with other pharmacological, and non-pharmacological agents. In clinical 163 
practice, eplerenone is administered at higher doses than spironolactone, since it has been shown to 164 
be inferior in lowering blood pressure in primary aldosteronism in a randomized head to head 165 
comparison (30) (see Table 1). 166 
 167 
Drug titration in medically treated PA patients 168 
Optimal medical therapy is crucial to prevent the complications of PA. As there is not a “one size fits 169 
all” therapy regimen in PA, individualized treatment is key for optimal patient benefit. In addition to 170 
normotensive blood pressure, causally targeting the aldosterone excess by pharmacological MR 171 
receptor blockade constitutes an important treatment goal and conveys prognostic superiority over 172 
optimal blood pressure control in PA (1).  173 
For optimal disease control, regular follow up visits, including blood pressure monitoring and 174 
surveillance of serum potassium levels are of utmost importance (see flow chart 1). MR antagonists 175 
should be administered at a low starting dose (e.g. 25 mg spironolactone per day) with a slow 176 
uptitration according to blood pressure. In our outpatient clinic, we re-evaluate the patients after 4 177 
weeks to amend the spironolactone dose. Although hyperkalemia rarely limits up-titration because 178 
of the underlying hyperaldosteronism favoring hypokalemia, serum potassium levels should be 179 
monitored frequently in the beginning. It is our experience that 50 mg per day of spironolactone are 180 
often sufficient. Higher doses are not well tolerated, particularly in males because of the anti-181 
androgenic actions leading to painful gynecomastia, erectile dysfunction and loss of libido. In 182 
females, spironolactone can be used in higher doses, but doses above 100 mg often induce 183 
menstrual irregularities. If blood pressure control is suboptimal despite maximum tolerated MRA 184 
dose, further antihypertensive drugs should be added (1).  185 
Plasma renin activity might constitute an additional marker to evaluate successful aldosterone 186 
blockade (3). In case of persistent renin suppression, increasing the MRA dose might be considered, 187 
provided that there are no contraindications (e.g. antiandrogen side effects, elevated serum 188 
potassium levels or hypotension). Another alternative, or adjunct, might be dietary sodium 189 
restriction (24). In our experience, primary aldosteronism patients tend to spontaneously consume a 190 
very high salt diet often exceeding 10 g per day, potentially because of a shift in the sensory salt 191 
perception (Adolf et al., manuscript under review).  192 
In case of poor blood pressure control, low serum potassium and suppressed renin activity despite 193 
high doses of MRA medication, non-compliance must be considered (1). 194 
If eplerenone is used for PA treatment, an important consideration is the significantly shorter half-life 195 
compared to spironolactone. For an adequate aldosterone antagonism administration at least twice 196 
daily is necessary. In case of an insufficient response, a three times per day administration should be 197 
considered. In general, eplerenone must be dosed twice as high as spironolactone for therapeutic 198 




Early diagnosis, and specific treatment, have prognostic relevance in primary aldosteronism. In 203 
unilateral disease, the standard of care remains surgical treatment via adrenalectomy. This causally 204 
addresses aldosterone excess, as well as potentially accompanying hypercortisolemia.  205 
In bilateral disease, medical treatment with MR-antagonists is the gold standard. Slow drug titration 206 
under regular supervision improves adherence, and disease control. Primary markers of adequate 207 
treatment are potassium levels in the upper normal range and optimal blood pressure control. 208 
Plasma renin activity has been suggested as an adjunct marker that might provide additional 209 
information. In case of persistently suppressed plasma renin activity, adjustment of the MRA therapy 210 
should be considered, provided the absence of contraindications. It is important to not draw 211 
precipitous conclusions from the Hundemer et al. study. More data from larger populations is 212 
needed to confirm these results, especially in the context of salt consumption and compliance. 213 
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Table 1: Comparison of the pharmacological profiles of MR antagonists.  337 
*Status is country-dependent 338 
 spironolactone eplerenone 
Approved for PA treatment yes No* 
Half-life (h) 24-58 3-4 
Active metabolites yes no 
Hepatic elimination (drug 
interaction) 
no yes 
Administration 1x/d 2-3x/d 
Starting Dose 25mg – 0 – 0  25mg – 0 – 25mg 
Anti-androgenic side effects yes  
(painful gynecomastia, erectile 





Flow chart 1: MRA dose titration 
